Recently, a novel BET-inhibitor, GS-5829, has been pre-clinically tested in CLL, which inhibited key signaling pathways and several oncogenes including MYC, Akt, ERK1/2, NF-κB, and BLK. GS-5829 induced apoptosis of primary CLL cells irrespective of their IGHV mutational status [158]. The gene discussed is AKT1; the disease is B-cell chronic lymphocytic leukemia.